Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model

Pharmaceutical Research

Volumn 23, Issue 9, 2006, Pages 2094-2106

  Fulzele, Suniket V ^a   Chatterjee, Abhijit ^a   Shaik, Madhu Sudhan ^a,b   Jackson, Tanise ^a   Singh, Mandip ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b Barr Laboratories Inc   (United States)

Author keywords

Celecoxib; Docetaxel; Inhalation; Nose only exposure; Orthotopic lung tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CELECOXIB; DOCETAXEL; INTERLEUKIN 8; PROSTAGLANDIN E2; PYRAZOLE DERIVATIVE; SULFONAMIDE; TAXOID;

AEROSOL; ANIMAL; ARTICLE; CANCER TRANSPLANTATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MOUSE; PATHOLOGY; XENOGRAFT;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DINOPROSTONE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENOUS; INTERLEUKIN-8; LUNG NEOPLASMS; MICE; NEOPLASM TRANSPLANTATION; PYRAZOLES; SULFONAMIDES; TAXOIDS; TRANSPLANTATION, HETEROLOGOUS;

EID: 33750577967     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9074-6     Document Type: Article

References (47)

1. Y. Tian, M. E. Klegerman, M. E. Hickey, and A. J. Hickey. Evaluation of microparticles containing doxorubicin suitable for aerosol delivery to the lungs, PDA. J. Pharm. Sci. Technol. 58:266-275 (2004).
2. Y. Zou, H. Fu, S. Ghosh, D. Farquhar, and J. Klostergaard. Antitumor activity of hydrophilic paclitaxel copolymer prodrug using locoregional delivery in human orthotopic non-small cell lung cancer xenograft models. Clin. Cancer Res. 10:7382-7391 (2004).
3. T. Tatsumura and S. Kagamimori. Further study of nebulization chemoctherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical. Br. J. Cancer 68:1146-1149 (1993).
4. V. Knight, N. V. Koshkina, J. C. Waldrep, B. Giovanells, and G. E. Gilbert. Anticancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenograft in nude mice. Cancer Chemother. Pharmacol. 44:177-186 (1999).
5. N. V. Koshkina, J. C. Waldrep, L. E. Roberts, S. Melton, and V. Knight. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin. Cancer Res. 7:3258-3262 (2001).
6. N. V. Koshkina, V. Knight, G. E. Gilbert, E. Golunski, L. E. Roberts, and J. C. Waldrep. Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel, with 5% CO2 enriched air: pharmacokinetic studies. Cancer Chemother. Pharmacol. 47:451-456 (2001).
7. N. V. Koshkina and E. S. Kleinerman. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int. J. Cancer 116(3):458-463 (2005).
8. N. V. Koshkina, B. Giovanells, L. E. Roberts, G. E. Gilbert, and V. Knight. Cyclosporin A Aerosol improves the anticancer effect of Paclitaxel aerosol in mice. J. Aerosol Med. 17:7-14 (2004).
9. M. Leahy, R. L. Ornbrg, Y. Wang, B. S. Zweifel, A. T. Koki, and J. L. Masferrer. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62:625-631 (2002).
10. T. Hida, K-I. Kozaki, H. Muramatsu, A. Masuda, S. Shimizu, T. Mitsudomi, T. Sugiura, M. Ogawa, and T. Takahasi. Cyclo-oxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res. 6:2006-2011 (2000).
11. A. Haynes, M. S. Shaik, A. Chatterjee, and M. Singh. Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line. Pharm. Res. 20(9):1485-1495 (2003).
12. A. Haynes, M. S. Shaik, A. Chatterjee, and M. Singh. Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer. Pharm. Res. 22(3):427-439 (2005).
13. S. D. Solomon, J. J. V. McMurray, M. A. Pfeffer, J. Wittes, R. Flower, P. Finn, W. F. Anderson, A. Zauber, E. Hawk, and M. Bertagnolli. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl. J. Med. 352:1071-1080 (2005).
14. E. B. Haura. Treatment of advanced non-small cell lung cancer: a review of current randomized clinical trials and examination of emerging therapies. Cancer Control. 8(4):326-336 (2001).
15. A. Argiris, V. Kut, L. Luong, and M. J. Avram. Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer. Invest. New Drugs. 3:49-59 (2005).
16. A. Onn, T. Isobe, W. Wu, S. Itasaka, T. Shintani, K. Shibuya, Y. Kenji, M. O'Reilly, I. J. Fidler, and R. Herbst. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer. Clin. Cancer Res. 10:8613-8619 (2004).
17. H. H. Luh and T. Che. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin. Exp. Metastasis. 22(4):319-329 (2005).
18. M. S. Shaik, A. Chatterjee, T. Jackson, and M. Singh. Enhancement of anti-tumor activity of docetaxel by celecoxib in lung tumors. Int. J. Cancer. 118(2):396-404 (15 January 2006).
19. O. C. Trifan, W. F. Durham, V. S. Salazar, J. Horton, B. D. Levine, B. S. Zweifel, T. W. Davis, and J. L. Masferrer. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res. 62:5778-5784 (2002).
20. M. Kohlhaufl, K. Haussinger, F. Stanzel, A. Markus, J. Tritschler, A. Muhlhofer, A. Morresi-Hauf, I. Golly, G. Scheuch, B. H. Jany, and H. K. Biesalski. Inhalation of aerosolized vitamin a: reversibility of metaplasia and dysplasia of human respiratory epithelia - a prospective pilot study. Eur. J. Med. Res. 7:72-78 (2002).
21. C. L. Leach, P. J. Davidson, B. E. Hasselquist, and R. J. Boudreau. Lung deposition of hydrofluroalkane-134a Beclomethasone Is greater than that of chloroflurocarbon fluticasone and chloroflurocarbon beclomethasone: a crossover study in healthy volunteers. Chest. 122:510-516 (2002).
22. Z. Wang, H. T. Chen, W. Roa, and W. H. Finlay. Farnesol for aerosol inhalation: nebulization and activity against human lung cancer cells. J. Pharm. Pharmaceut. Sci. 6:95-100 (2003).
23. L. W. Wattenberg, T. S. Wiedmann, and R. D. Estensen. Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res. 57:5489-5492 (1997).
24. S. Sharma, D. White, A. R. Imondi, M. E. Placke, D. M. Vali, and M. G. Kris. Development of inhalational agents for oncologic use. J. Clin. Oncol. 19:1839-1847 (2001).
25. A. R. Dahl, I. M. Grossi, D. P. Houchens, L. J. Scovell, M. E. Placke, A. R. Imondi, G. D. Stoner, L. M. Deluca, D. Wang, and J. L. Mulshine. Inhaled isotretinoin (13-cis Retinoic acid) is an effective lung cancer chemopreventive agent in A/J mice at low doses: a pilot study. Clin. Cancer Res. 6:3015-3024 (2000).
26. O. G. Raabe, M. A. Bayati, S. V. Teafue, and A. Rasolt. Regional deposition of inhaled monodisperse coarse and fine aerosol particles in small laboratory animals. Ann. Occup. Hyg. 32(Suppl 1):53-63 (1988).
27. M. V. Varma and R. Panchagnula. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur. J. Pharm. Sci. 25(4-5):445-453 (July-August 2005).
28. Z. Zhang and S. S. Feng. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials. 27(2):262-270 (January 2006).
29. Z. Saidi and K. Boris. Aqueous composition containing corticosteroids for nasal and pulmonary delivery. US patent. 6,241,969(2001).
30. S. Somavarapu, S. Pandit, G. Gradasi, M. Bandera, E. Ravichandran, and O. H. Alpar. Effect of vitamin E TPGS on immune response to nasally delivered diphtheria toxoid loaded poly(caprolactone) microparticles. Int. J. Pharm. 298(2):344-347 (July 2005).
31. S. F. Jia, L. L. Worth, and E. S. Kleinerman. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin. Exp. Metastasis. 17:501-506 (1999).
32. A. E. Hershey, I. D. Kurzman, L. J. Forrest, C. A. Bohling, M. Stonerook, M. E. Placke, A. R. Imondi, and D. M. Vail. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: Proof of principle using dogs with spontaneously occurring tumors as a model. Clin. Cancer Res. 5:2653-2659 (1999).
33. F. Gagnadoux and T. Urban. Aerosol delivery of chemotherapy in an orthotopic model of lung cancer. Eur. Respir. J. 26:1-5 (2005).
34. S. V. Fulzele, M. S. Shaik, A. Chatterjee, and M. Singh. Anticancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549. J. Pharm. Pharmacol. 58(3):327-336 (2006).
35. E. Nakata, K. A. Mason, N. Hunter, A. Hussain, U. Raju, A. Liao, and K. K. Lang. Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int. J. Radiat. Oncol. Biol. Phys. 58(2):369-375 (2004).
36. B. S. Zweifel, T. W. Davis, R. L. Ornberg, and J. L. Masferrer. Direct evidence for a rolw of cyclooxygenase-2 derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res. 62:6706-6711 (2002).
37. T. W. Davis, J. M. O'Neal, M. D. Pagel, B. S. Zweifel, P. P. Mehta, D. M. Heuvelman, and J. L. Masferrer. Synergy between celecoxib and radiotherapy results from inhibition of cyclo-oxygenase-2 derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res. 64:279-285 (2004).
38. V. Nadithe, M. Rahmatalla, W. H. Finlay, J. R. Mercer, and J. Samuel. Evaluation of nose-only aerosol inhalation chamber and comparison of experimental results with mathematical simulation of aerosol deposition in mouse lungs. J. Pharm. Sci. 92(5):1066-1076 (2003).
39. T. L. McLemore, M. C. Liu, and P. C. Blank. Novel intrapulmonary model for orthotopic propogation of human lung cancers in athymic mice. Cancer Res. 47:5132-5140 (1987).
40. T. L. McLemore, J. C. Eggleston, and R. H. Shoemaker. Comparison of intrapulmonary, percutaneous intrathorasic and subcutaneous models for the propogation of human pulmonary and non-pulmonary cell lines in athymic nude mice. Cancer Res. 48:2880-2886 (1988).
41. G. H. Yoo, M. P. Piechocki, J. F. Ensley, T. Nguyen, J. Oliver, H. Meng, D. Kewson, T. Y. Shibuya, F. Lonardo, and M. S. Tainsky. Docetaxel induced gene expression patterns in head and neck aquamous cell carcinoma using cDNA microarray and power blot. Clin. Cancer Res. 8(12):3910-3921 (2002).
42. O. Micheau, E. Solary, A. Hammann, F. Martin, and M. T. Dimanche-Boitrel. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J. Natl. Cancer Inst. 89(11):783-789 (4 June 1997), .
43. Y. Ming, H. Deng, J. M. Zhao, D. Dong, and X. Tan. PPAR-gamma pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells. World J. Gastroenterol. 9(6):1220-1226 (2003).
44. V. G. Keshamouni, D. A. Arenberg, R. C. Reddy, M. J. Newstead, S. Anthwal, and T. J. Standiford. PPAR-gamma activation inhibits angiogenesis by blocking ELR + CXC chemokine production in non-small cell lung cancer. Neoplasia. 7(3):294-301 (May 2005).
45. E. S. White, R. M. Strieter, and D. A. Arenberg. Chemokines as therapeutic targets in non-small cell lung cancer. Curr. Med. Chem. Anti-Canc. Agents. 2(3):403-417 (2002), May.
46. J. L. Masferrer, K. M. Leahy, A. T. Koki, B. S. Zweifel, S. L. Settle, B. M. Woerner, D. A. Edwards, A. G. Flickinger, R. J. Moore, and K. Seibert. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:1306-1311 (2000).
47. I. Csiki, T. Dang, A. Gonzalez, A. Sandler, D. Carbone, H. Choy, N. Campbell, B. Garcia, J. Morrow, and D. H. Johnson. Cyclooxygenase-2 (COX-2) inhibition docetaxel (Txt) in recurrent nonsmall cell lung cancer (NSCLC): preliminary results of a Phase II trail (THO-0054). Proc. Am. Soc. Clin. Oncol. 21:A1187 (2002).